The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
The polymorphisms at the α-chain of the IL-7 receptor (IL7RA) have been related to T-cell homeostasis and development and may contribute to immune system deregulation. In the present study, we analyzed the association between IL7RA polymorphisms and the progression of liver fibrosis in patients infe...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5942816?pdf=render |
| _version_ | 1811343385738346496 |
|---|---|
| author | María Ángeles Jiménez-Sousa Ana Zaida Gómez-Moreno Daniel Pineda-Tenor Luz Maria Medrano Juan José Sánchez-Ruano Amanda Fernández-Rodríguez Tomas Artaza-Varasa José Saura-Montalbán Sonia Vázquez-Morón Pablo Ryan Salvador Resino |
| author_facet | María Ángeles Jiménez-Sousa Ana Zaida Gómez-Moreno Daniel Pineda-Tenor Luz Maria Medrano Juan José Sánchez-Ruano Amanda Fernández-Rodríguez Tomas Artaza-Varasa José Saura-Montalbán Sonia Vázquez-Morón Pablo Ryan Salvador Resino |
| author_sort | María Ángeles Jiménez-Sousa |
| collection | DOAJ |
| description | The polymorphisms at the α-chain of the IL-7 receptor (IL7RA) have been related to T-cell homeostasis and development and may contribute to immune system deregulation. In the present study, we analyzed the association between IL7RA polymorphisms and the progression of liver fibrosis in patients infected with HCV. We carried out a retrospective study with a design consisting of repeated measurements in 187 HCV-infected patients, to study the risk prediction of liver fibrosis progression using genetic factors. We genotyped the rs6897932, rs987106 and rs3194051 IL7RA polymorphisms using the Agena Bioscience's MassARRAY. Transient elastography was used to measure liver stiffness. The used cut-offs were: <7.1 kPa (F0-F1), 7.1-9.4 kPa (F2; significant fibrosis), 9.5-12.4 kPa (F3; advanced fibrosis), and ≥12.5 kPa (F4; cirrhosis). All HCV genotypes were analyzed. The median of follow-up time was 47.9 months. Baseline liver stiffness measurement (LSM) values did not show significant statistical differences for IL7RA genotypes (p>0.05). In univariate analysis, the rs6897932 T allele had a positive relationship with an increase in LSM (arithmetic mean ratio (AMR) = 1.21 (95%CI = 1.08; 1.36); p = 0.001), progression to advanced fibrosis (F≥3) (odds ratio (OR) = 2.51 (95%CI = 1.29; 4.88); p = 0.006) and progression to cirrhosis (F4) (OR = 2.71 (95%CI = 0.94; 5.03); p = 0.069). In multivariable analysis, the rs6897932 T allele was related to a higher increase of LSM values during follow-up (adjusted AMR = 1.27 (95%CI = 1.13; 1.42); p<0.001) and higher odds of progression to advanced fibrosis [adjusted OR = 4.46 (95%CI = 1.87; 10.62); p = 0.001], and progression to cirrhosis [adjusted OR = 3.92 (95%CI = 1.30; 11.77); p = 0.015]. Regarding IL7RA rs987106 and rs3194051 polymorphisms, we did not find significant results except for the relationship between IL7RA rs987106 and the increase in LSM values [adjusted OR = 1.12 (95%CI = 1.02; 1.23); p = 0.015]. The IL7RA rs6897932 polymorphism seems to be related to increased risk of liver fibrosis progression in HCV-infected patients. Thus, the rs6897932 polymorphism could be related to the physiopathology of CHC and might be used to successfully stratify the risk of CHC progression. |
| first_indexed | 2024-04-13T19:28:26Z |
| format | Article |
| id | doaj.art-e8907a92994d4f2cb651a875bfea0304 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T19:28:26Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e8907a92994d4f2cb651a875bfea03042022-12-22T02:33:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019711510.1371/journal.pone.0197115The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.María Ángeles Jiménez-SousaAna Zaida Gómez-MorenoDaniel Pineda-TenorLuz Maria MedranoJuan José Sánchez-RuanoAmanda Fernández-RodríguezTomas Artaza-VarasaJosé Saura-MontalbánSonia Vázquez-MorónPablo RyanSalvador ResinoThe polymorphisms at the α-chain of the IL-7 receptor (IL7RA) have been related to T-cell homeostasis and development and may contribute to immune system deregulation. In the present study, we analyzed the association between IL7RA polymorphisms and the progression of liver fibrosis in patients infected with HCV. We carried out a retrospective study with a design consisting of repeated measurements in 187 HCV-infected patients, to study the risk prediction of liver fibrosis progression using genetic factors. We genotyped the rs6897932, rs987106 and rs3194051 IL7RA polymorphisms using the Agena Bioscience's MassARRAY. Transient elastography was used to measure liver stiffness. The used cut-offs were: <7.1 kPa (F0-F1), 7.1-9.4 kPa (F2; significant fibrosis), 9.5-12.4 kPa (F3; advanced fibrosis), and ≥12.5 kPa (F4; cirrhosis). All HCV genotypes were analyzed. The median of follow-up time was 47.9 months. Baseline liver stiffness measurement (LSM) values did not show significant statistical differences for IL7RA genotypes (p>0.05). In univariate analysis, the rs6897932 T allele had a positive relationship with an increase in LSM (arithmetic mean ratio (AMR) = 1.21 (95%CI = 1.08; 1.36); p = 0.001), progression to advanced fibrosis (F≥3) (odds ratio (OR) = 2.51 (95%CI = 1.29; 4.88); p = 0.006) and progression to cirrhosis (F4) (OR = 2.71 (95%CI = 0.94; 5.03); p = 0.069). In multivariable analysis, the rs6897932 T allele was related to a higher increase of LSM values during follow-up (adjusted AMR = 1.27 (95%CI = 1.13; 1.42); p<0.001) and higher odds of progression to advanced fibrosis [adjusted OR = 4.46 (95%CI = 1.87; 10.62); p = 0.001], and progression to cirrhosis [adjusted OR = 3.92 (95%CI = 1.30; 11.77); p = 0.015]. Regarding IL7RA rs987106 and rs3194051 polymorphisms, we did not find significant results except for the relationship between IL7RA rs987106 and the increase in LSM values [adjusted OR = 1.12 (95%CI = 1.02; 1.23); p = 0.015]. The IL7RA rs6897932 polymorphism seems to be related to increased risk of liver fibrosis progression in HCV-infected patients. Thus, the rs6897932 polymorphism could be related to the physiopathology of CHC and might be used to successfully stratify the risk of CHC progression.http://europepmc.org/articles/PMC5942816?pdf=render |
| spellingShingle | María Ángeles Jiménez-Sousa Ana Zaida Gómez-Moreno Daniel Pineda-Tenor Luz Maria Medrano Juan José Sánchez-Ruano Amanda Fernández-Rodríguez Tomas Artaza-Varasa José Saura-Montalbán Sonia Vázquez-Morón Pablo Ryan Salvador Resino The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. PLoS ONE |
| title | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| title_full | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| title_fullStr | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| title_full_unstemmed | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| title_short | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| title_sort | il7ra rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis c repeated measurements design |
| url | http://europepmc.org/articles/PMC5942816?pdf=render |
| work_keys_str_mv | AT mariaangelesjimenezsousa theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT anazaidagomezmoreno theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT danielpinedatenor theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT luzmariamedrano theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT juanjosesanchezruano theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT amandafernandezrodriguez theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT tomasartazavarasa theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT josesauramontalban theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT soniavazquezmoron theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT pabloryan theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT salvadorresino theil7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT mariaangelesjimenezsousa il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT anazaidagomezmoreno il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT danielpinedatenor il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT luzmariamedrano il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT juanjosesanchezruano il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT amandafernandezrodriguez il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT tomasartazavarasa il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT josesauramontalban il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT soniavazquezmoron il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT pabloryan il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign AT salvadorresino il7rars6897932polymorphismisassociatedwithprogressionofliverfibrosisinpatientswithchronichepatitiscrepeatedmeasurementsdesign |